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Group and serocomplex cross-reactive epitopes have been identified in the envelope (E) protein
of several flaviviruses and have proven critical in vaccine and diagnostic antigen development.
Here, we performed site-directed mutagenesis across the E gene of a recombinant expression
plasmid that encodes the Japanese encephalitis virus (JEV) premembrane (prM) and E proteins
and produces JEV virus-like particles (VLPs). Mutations were introduced at I135 and E138 in
domain I; W101, G104, G106 and L107 in domain II; and T305, E306, K312, A315, S329,
S331, G332 and D389 in domain III. None of the mutant JEV VLPs demonstrated reduced activity
to the five JEV type-specific mAbs tested. Substitutions at W101, especially W101G, reduced
reactivity dramatically with all of the flavivirus group cross-reactive mAbs. The group and JEV
serocomplex cross-reactive mAbs examined recognized five and six different overlapping
epitopes, respectively. Among five group cross-reactive epitopes, amino acids located in domains
I, II and III were involved in one, five and three epitopes, respectively. Recognition by six JEV
serocomplex cross-reactive mAbs was reduced by amino acid substitutions in domains II and III.
These results suggest that amino acid residues located in the fusion loop of E domain II are the
most critical for recognition by group cross-reactive mAbs, followed by residues of domains III and
I. The amino acid residues of both domains II and III of the E protein were shown to be important in
the binding of JEV serocomplex cross-reactive mAbs.
INTRODUCTION
Serological testing completed in the early 20th century
classifies arboviruses into groups A and B by serological
cross-reactivity. Japanese encephalitis virus (JEV) and
other flaviviruses fall into group B (Casals & Brown,
1954). Japanese encephalitis is the leading cause of
encephalitis in humans in Asian countries (Vaughn &
Hoke, 1992). JEV belongs to the family Flaviviridae and has
a positive-sense ssRNA genome of approximately 11 000 nt in
length (Chambers et al., 1990; Lindenbach & Rice, 2003).
Recent history has seen a global resurgence of diseases caused
by arboviruses once thought to be under control, such as JEV,
tick-borne encephalitis virus (TBEV) and yellow fever virus,
as well as viruses with expanded geographical distribution and
disease severity, such as West Nile virus (WNV) and dengue
virus serotypes 1–4 (DENV-1 to -4) (Lanciotti et al., 1999;
Mackenzie et al., 2004). Co-circulating flaviviruses and
compulsory immunization confound serodiagnosis and can
impact pathogenesis (Halstead, 1988).
The flavivirus envelope (E) glycoprotein contains three
structural and functional domains (Kanai et al., 2006; Rey
et al., 1995). E domain I (EDI) contains predominantly
type-specific non-neutralizing (non-NT) epitopes and is an
eight-stranded b-barrel. E domain II (EDII) contains cross-
reactive epitopes eliciting both weakly NT and non-NT
antibodies and contains the highly conserved internal
fusion peptide (FP). E domain III (EDIII) has an Ig-like
structure and contains the majority of type-specific,
potently NT epitopes as well as the primary receptor-
binding motifs (Beasley & Barrett, 2002; Crill & Chang,
2004; Kanai et al., 2006; Oliphant et al., 2006; Rey et al.,
1995; Roehrig et al., 1983, 1989, 1990, 1998; Stiasny et al.,
2006). Flavivirus infections elicit antibodies that cross-react
with other members of the flavivirus group, as well as
antibodies that cross-react with other viruses within the
same serocomplex. Recently, amino acids located in the
highly conserved E FP of EDII, particularly W101, G104,
A supplementary figure and table are available with the online version of
this paper.
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G106 and L107, have been identified as important
flavivirus group cross-reactive epitope determinants in
DENV-2, TBEV, St Louis encephalitis virus, WNV and JEV
(Chiou et al., 2008; Crill & Chang, 2004; Lai et al., 2008;
Oliphant et al., 2006; Stiasny et al., 2006; Trainor et al.,
2007).
Complex cross-reactive epitopes were found to contain
residues in EDIII, including K305, K307, L308, E309, K310,
E311, V312, L387, L389 and W391, in DENV-2 and -3
(Crill et al., 2009; Gromowski et al., 2008; Matsui et al.,
2009; Sukupolvi-Petty et al., 2007). Here we present results
from mutagenesis of the JEV E protein and subsequent
epitope mapping utilizing murine mAb panels to identify
and ablate group and serocomplex cross-reactive epitopes.
Our mAb epitope mapping results identify five subtly
different group cross-reactive epitopes located in the
EDIIFP, centred on W101, and six different complex
cross-reactive epitopes, five of which are centred in the A
sheet and BCx loop of EDIII, but also include residues in
the EDIIFP.
RESULTS
mAb reactivity and epitope characterization
Epitope mapping of the JEV wild-type (WT) and mutant
virus-like particles (VLPs) was carried out using a collection
of five JEV-specific, six group cross-reactive and seven
complex cross-reactive murine mAbs (Tables 1, 2 and 3). An
antigen-capture ELISA (Ag-ELISA) was used to standardize
VLP concentrations and then to characterize individual VLP
reactivity with the mAb panel.
End-point titres for five JEV type-specific mAbs, 112, 503,
2F2, 2H4 and J13 14 H5-2, against JEV WT VLPs ranged
from 103.00 to 105.86 (Table 1). None of the JEV type-
specific mAbs examined demonstrated reduced reactivity
with any of the mutant JEV VLPs. In contrast, some of
these mAbs experienced enhanced reactivity with mutant
VLPs compared with WT (e.g. mAb 112 with W101, T305
and A315 substitutions). These data suggest that some
substitutions not only maintain VLP recognition by JEV
type-specific mAbs, but increase their reactivity.
Six flavivirus group cross-reactive mAbs, 6B6C-1, 4G2, 23-1,
23-2, 6B3B-3 and 5-2, reacted with WT JEV VLP, with titres
ranging from 104.43 to ¢106.82 (Table 2). Substitutions at
W101, especially W101G, reduced reactivity dramatically
with all six flavivirus group-reactive mAbs. The reactivity of
mAbs 6B6C-1, 4G2 and 5-2 was also reduced by the G104H
and G106K substitutions, and the reactivities of all group
cross-reactive mAbs except 6B6C-1 were reduced by the
L107D substitution. Of the EDI substitutions, only E138K
reduced reactivity with mAb 5-2. The reactivity of 6B6C-1,
4G2 and 6B3B-3 was additionally reduced by substitutions
T305E, K312E, A315E, A315R, S329A, S331K, G332R and
D389G. Unexpectedly, the reactivity of 6B6C-1 was en-
hanced against VLPs containing mutations L107D, I135S or
E138K. These results suggest that, whilst amino acid residues
of EDII are most critical for group cross-reactive mAbs,
Table 1. Type-specific mAb reactivity against WT and mutant VLPs
mAb end-point reactivity of WT and mutant VLPs was determined via Ag-ELISA and is expressed on a logarithmic scale. ND, Not determined. Bold
type indicates a mutant VLP Ag-ELISA end-point titre .4-fold that of WT VLPs.
VLP MHIAF Type-specific mAbs (reciprocal log10 end-point titre)
112 503 2F2 2H4 J3 14 H5-2
WT 5.39 5.39 3.95 5.86 5.86 3.00
W101G 5.39 4.91 3.95 5.86 5.86 ND
W101K 5.40 6.00 3.95 ND ND ND
W101E 5.40 6.00 3.95 ND ND ND
W101F 5.40 ¢6.40 3.95 ND ND ND
G104H 5.40 ND ND 5.86 5.86 ,3
G106K 5.40 5.86 3.95 6.40 5.86 3.00
L107D 5.40 5.86 3.95 5.86 5.86 3.90
I135S 5.40 ND ND 5.86 5.86 3.00
E138K 5.90 ND ND 5.86 5.86 3.00
T305E 5.40 6.00 3.95 ND ND ND
T305H 5.40 6.00 3.95 ND ND ND
E306G 5.41 ND ND ¢5.71 ¢5.71 ND
K312E 5.86 5.39 3.95 6.40 5.86 ND
A315E 5.40 6.00 3.95 ND ND ND
A315R 5.40 5.40 3.95 ND ND ND
S329A 5.41 ND ND 5.71 5.71 ND
S331K 5.41 ND ND 5.71 5.41 ND
G332R 5.41 ND ND 5.71 5.41 ND
D389G 5.41 ND ND 5.71 5.41 ND
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residues of EDIII can also be involved in the epitopes
recognized by these mAbs.
The reactivity of seven JEV serocomplex cross-reactive mAbs,
2B5B-3, 6B4A-10, 16, 109, 203, 1B5D-1 and 7A6C-5, with
WT JEV VLPs was demonstrated by end-point titres ranging
from 103.95 to¢106.82 (Table 3). Of amino acid substitutions
located in EDII, W101G reduced reactivity with mAbs 2B5B-
3, 6B4A-10 and 1B5D-1; G104H with mAb 16; and G106K
with 2B5B-3 and 1B5D-1. Neither of the EDI amino acid
substitutions affected the reactivity of the JEV serocomplex
cross-reactive mAbs examined. The reactivity of mAbs 6B4A-
10, 109 and 1B5D-1 was reduced by EDIII substitutions
A315E and A315R; mAbs 203 and 1B5D-1 by K312E; and
mAb 16 by T305H, S331K and D389G. Mutations L107D
and T305E appeared to enhance the reactivity of mAb 6B4A-
10, and mAb 16 was affected similarly by the W101K
mutation. These results suggest that, for individual complex
cross-reactive mAbs, residues in either EDII or EDIII can
play critical roles in the epitopes recognized by these mAbs,
and that for three mAbs (6B4A-10, 16 and 1B5D-1), there are
epitope determinants in both EDII and EDIII.
Cross-reactive epitopes on the JEV E protein
Based on the pattern of mAb reactivity with JEV WT and
mutant VLPs, flavivirus group and JEV serocomplex
cross-reactive mAbs can be classified into five and six
different epitope groups, respectively (Table 4). The
differential patterns of substitutions in EDI, EDII and
EDIII, acting as epitope determinants for the six flavivirus
group cross-reactive mAbs examined here, suggest the
existence of at least five overlapping yet distinct epitopes
recognized by these antibodies. All group cross-reactive
mAbs examined were affected by substitutions at amino
acid W101. Similarly, G104, G106 and L107 appear to be
incorporated into three group cross-reactive epitopes
(Table 4; Fig. 1). The epitopes recognized by 4G2, 6B3B-
3 and 6B6C-1 appear to additionally include different
subsets of amino acids in EDIII; only one of the amino
acid residues examined in EDI appears to be involved in
any of the group cross-reactive mAb epitopes (5-2). These
results suggest that the amino acid residues of the EDII
fusion loop, and especially W101G, are most critical to
group cross-reactive mAb epitopes, followed by residues
of EDIII and then EDI (Table 4; Fig. 1).
The seven JEV serocomplex cross-reactive mAbs examined
appeared to bind six different epitopes (Table 4). The
fusion loop amino acids seem to be involved in four
different JEV serocomplex cross-reactive epitopes, includ-
ing those bound by mAbs 2B5B-3, 6B4A-10, 16 and 1B5D-
1. However, W101 does not appear to play as critical a role
in the binding of these complex cross-reactive mAbs as it
Table 2. Group cross-reactive mAb reactivity against WT and mutant VLPs
mAb end-point reactivity of WT and mutant VLPs was determined via Ag-ELISA and is expressed on a logarithmic scale. ND, Not determined.
Underlining indicates a mutant VLP Ag-ELISA end-point titre reduced by .4-fold that of WT VLPs; bold type indicates a mutant VLP Ag-ELISA
end-point titre increased by .4-fold that of WT VLPs.
VLPs Group cross-reactive mAbs (reciprocal log10 end-point titre)
6B6C-1 4G2 23-1 23-2 6B3B-3* 5-2*
WT 5.39 6.40 ¢6.82 5.39 5.86 4.43
W101G ,3 ,3 ,3 ,3 ,3 ,3
W101K ,3 5.20 3.00 3.95 ,3 ,3
W101E ,3 5.20 3.00 ,3 ,3 ,3
W101F 3.95 ¢6.82 ¢6.82 5.39 4.80 ,3
G104H ,3 4.90 6.30 4.89 ND ,3
G106K 3.95 4.00 ¢6.82 5.39 ND ,3
L107D 6.39 ,3 3.00 3.40 ND ,3
I135S ¢6.82 ¢6.82 ¢6.82 5.39 ND 4.93
E138K 6.82 5.89 ¢6.82 5.39 ND 3.43
T305E 4.39 6.40 ¢6.82 5.39 5.40 5.03
T305H 5.39 6.40 ¢6.82 5.39 5.86 5.03
E306G 5.09 6.40 ND 5.41 5.71 ND
K312E 4.91 5.39 ¢6.82 5.39 ,3 4.43
A315E ,3 4.60 ¢6.82 5.39 ,3 4.43
A315R 4.09 4.60 ¢6.82 5.39 3.00 3.83
S329A 4.39 6.00 ND 5.41 3.60 ND
S331K ,3 5.39 ND 5.41 3.46 ND
G332R ,3 5.39 ND 5.11 4.20 ND
D389G ,3 4.60 ND 5.41 3.46 ND
*Subgroup cross-reactive mAbs.
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does for the group cross-reactive mAbs. The EDIII amino
acid residues investigated seem to be involved in five
different JEV serocomplex cross-reactive epitopes, affecting
the reactivity of mAbs 6B4A-10, 16, 109, 203 and 1B5D-1.
None of the six JEV serocomplex cross-reactive epitopes
appeared to include the EDI amino acid residues
investigated in this study. Also, none of the mutations
introduced in this study influenced the binding of mAb
7A6C-5, suggesting that this mAb recognizes an epitope
including residues beyond any of those examined in this
study (Table 3). These results suggest that the amino acid
residues of both EDII and EDIII are important in JEV
serocomplex cross-reactive mAb epitopes (Table 4; Fig. 1).
DISCUSSION
Flavivirus infections elicit protective antibody responses
primarily against the E glycoprotein (Kuno, 2003). Murine
mAb studies demonstrate that EDI contains predominantly
type-specific, EDIII both type-specific and complex cross-
reactive, and EDII predominantly broadly cross-reactive
epitopes (Crill & Chang, 2004; Oliphant et al., 2006;
Roehrig et al., 1983, 1989, 1990, 1998; Stiasny et al., 2006).
Here, we demonstrate that group cross-reactive epitopes
are affected most dramatically by substitutions of the
amino acid residues of the fusion loop of EDII, followed by
residues of EDIII and EDI. Amino acid residues of both
EDII and EDIII act as epitope determinants of JEV sero-
complex cross-reactive mAbs.
Table 3. Serocomplex cross-reactive mAb reactivity against WT and mutant VLPs
mAb end-point reactivity of WT and mutant VLPs was determined via Ag-ELISA and is expressed on a logarithmic scale. ND, Not determined.
Underlining indicates a mutant VLP Ag-ELISA end-point titre reduced by .4-fold that of WT VLPs; bold type indicates a mutant VLP Ag-ELISA
end-point titre increased by .4-fold that of WT VLPs.
VLPs Complex cross-reactive mAbs (reciprocal log10 end-point titre)
2B5B-3* 6B4A-10 16 109 203 1B5D-1D 7A6C-5D
WT ¢6.82 4.43 4.91 4.20 4.43 3.95 4.91
W101G 5.86 ,3 4.43 4.80 3.95 ,3 4.91
W101K ¢6.82 4.43 ¢6.11 4.80 4.80 4.55 4.91
W101E ¢6.82 4.43 5.51 4.80 4.80 4.55 4.91
W101F ¢6.82 4.43 5.51 4.80 4.43 4.55 5.51
G104H 6.30 3.93 ,3 ND ND 3.35 ND
G106K ,3 4.93 5.30 ND ND ,3 ND
L107D ¢6.82 5.43 5.30 ND ND 4.45 ND
I135S ¢6.82 4.93 4.40 ND ND 3.95 ND
E138K ¢6.82 4.93 4.40 ND ND 3.95 ND
T305E ¢6.82 ¢5.03 4.91 4.20 4.80 3.95 4.91
T305H ¢6.82 3.83 3.71 3.60 4.43 3.35 4.91
E306G 6.30 ND 4.91 ND ND ND 4.91
K312E ¢6.82 4.91 4.91 4.20 ,3 ,3 5.39
A315E ¢6.82 3.23 4.31 3.00 4.43 ,3 4.91
A315R ¢6.82 3.23 4.31 3.00 4.43 ,3 4.91
S329A 6.30 ND 4.91 ND ND ND 4.91
S331K 6.30 ND 4.20 ND ND ND 4.91
G332R 6.30 ND 4.91 ND ND ND 4.91
D389G 6.30 ND 4.20 ND ND ND 4.91
*Supercomplex cross-reactive mAbs.
DSubcomplex cross-reactive mAbs.
Table 4. Amino acid residues in the E protein influencing
group and serocomplex cross-reactive mAb recognition
GCR, Group cross-reactivity; CCR, complex cross-reactivity.
Class/
mAb
Domain residue
I II III
GCR
4G2 101, 104, 106, 107 312, 315, 331, 332, 389
6B3B-3 101, 312, 315, 329, 331, 332,
389
6B6C-1 101, 104, 106 305, 315, 329, 331, 332,
389
23-1, 23-2 101, 107
5-2 138 101, 104, 106, 107
CCR
2B5B-3 101, 106
16 104 305, 331, 389
203 312
1B5D-1 101,106 312, 315
6B4A-10 101 315
109 315
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The importance of residues within the flavivirus FP as
cross-reactive antigenic determinants has received atten-
tion (Crill & Chang, 2004; Crill et al., 2007; Oliphant et al.,
2006; Stiasny et al., 2006). Functional conservation across
the flaviviruses in the FP region leads to the strong cross-
reactive immunogenicity of this region. The fusion loop
appears to be buried at the EDIII interface of the adjacent E
protein that forms an E homodimer in the mature virion,
seemingly precluding antibody binding to this region
(Modis et al., 2004; Nybakken et al., 2006; Rey et al., 1995;
Stiasny et al., 2006). However, decreases in dimer affinity
within the virion, especially in different pH environments,
could allow antibodies access to buried residues near the
fusion loop. Previously published results predicted that
EDIIFP residues W101, G104, G106 and L107 would be
involved in flavivirus group cross-reactive epitopes (Chiou
et al., 2008; Crill & Chang, 2004; Crill et al., 2007; Lai et al.,
2008). However, we are surprised that JEV serocomplex
cross-reactive epitopes are also influenced by residues
W101, G104, G106 and L107.
Compared with substitutions of the other conserved
residues of the fusion loop, the W101G substitution dra-
matically reduces reactivity with all flavivirus group cross-
reactive mAbs investigated. In support of the important
role of W101 for flavivirus group cross-reactive antibody
recognition, a recent study demonstrated that the pre-
dominantly cross-reactive polyclonal human sera generated
during primary and secondary DENV infection recognizes
epitopes that involve the W101 residue at the fusion loop
of EDII (Lai et al., 2008). Additionally, all of the broadly
cross-reactive mAbs generated from WNV-infected mice
that recognized the WT EDI–EDII tryptic E fragment
exhibited significantly reduced binding for W101 mu-
tant antigens (Oliphant et al., 2006). Therefore, the W101
residue appears to be the fusion loop residue incorporated
most frequently into the overlapping epitopes of antibodies
recognizing this antigenic region.
Although the most critical amino acid residues of the
group cross-reactive epitopes seem to be located in the
fusion loop of EDII, the residues of EDIII also play an
important role. On the mature virion, the E protein forms
a structurally compact head-to-tail dimer (Modis et al.,
2004; Nybakken et al., 2006; Rey et al., 1995). A previous
study suggested the involvement of the conserved residues
393–401 of EDIII in the binding of group cross-reactive
mAbs (Falconar, 2008). Although we did not investigate
substitutions in this region of the E protein, in this study
we found several residues in EDIII, including T305, K312,
A315, S329, S331, G332 and D389, that influenced three of
five group cross-reactive epitopes. The well-characterized,
overlapping epitopes of mAbs 4G2 and 6B6C-1 were
affected by substitutions at S331 and G332, which in a
previous study also influenced mAb binding of a JEV type-
specific epitope, and at D389, which is involved in receptor
binding (Chiou & Chen, 2007).
The DENV complex cross-reactive mAbs have been shown
to recognize a set of overlapping epitopes that form a single
antigenic site on the lateral surface of domain III,
consisting of residues V305, L306, K308, E309, V310,
K325, G381, D382, A384, K386, I387, W389 and R391
(Matsui et al., 2009). In this study, we characterized six JEV
complex cross-reactive epitopes by identifying amino acid
residues of both EDII and EDIII that influence the binding
of several JEV serocomplex cross-reactive mAbs. However,
we did not identify a single most critical residue in the JEV
serocomplex cross-reactive epitopes, analogous to W101 in
flavivirus group-reactive epitopes.
(a)
(b)
138
305
312315 329
331
332
389
107
101
106104
Fig. 1. Structural locations of JEV E protein
cross-reactive epitope residues. (a) Amino
acid positions reactive with group cross-
reactive mAbs; (b) amino acid positions
reactive with serocomplex cross-reactive
mAbs. Amino acid shading represents the
number of mAb epitopes affected according
to Table 4 (darkest, involved in five mAb
epitopes; lightest, involved in one mAb epi-
tope).
Epitope analysis of JEV E protein
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Major conformational changes induced by these substitu-
tions are unlikely because end-point titres of polyclonal
murine hyperimmune ascitic fluid (MHIAF) are very
similar between these mutants and WT JEV VLPs, although
minor conformational alterations cannot be ruled out.
Nevertheless, the mean area buried by the recognition of
antibody–antigen complex is approximately 1600(±400) A˚2
(Lo Conte et al., 1999). In this study, the longest distance
between the EDIIFP and the EDIII residues (G104 and
D389) recognized by mAbs 4G2, 6B6C-1 and 16 (Table 4)
is approximately 44.1 A˚ between domains within an E
dimer or 22.6 A˚ between domains across adjacent E dimers
of the mature virion. Moreover, in the context of adjacent
immature E trimers and dimers in partially mature virions,
the distance between such residues is unknown, but it
could be even closer than our estimation. Thus, it is
likely that these residues, acting as epitope determinants
for these cross-reactive mAbs, can be accommodated with-
in the footprint of a single mAb. Additionally, mutations
reducing E-specific mAb recognition do not appear to
be due to the alteration of prM cleavage, processing or
assembly, or VLP structure. prM processing, determined
by the furin cleavage site between pr and M, is not affected
by the E mutation, because, compared with WT VLP, the
seven VLP mutants expressed a similar ratio of E/prM (Fig.
S1, available in JGV Online). Viable mutant viruses (E138K
and D389G) were available from our previous study
(Chiou & Chen, 2007). We performed Ag-ELISA using
these two mutant viruses with selected mAbs. The results
support that the potential structural difference between
VLPs and infectious virus did not distort our results, as
E138K virions reduced mAb 5-2 binding by 8-fold and
D389G virions reduced mAb 4G2 and 16 binding by 32-
and 4-fold, respectively (data not shown; Ferlenghi et al.,
2001).
Interestingly, none of the mutated JEV VLPs used in this
study demonstrated reduced reactivity with JEV type-
specific mAbs, whilst some experienced altered binding of
flavivirus group-reactive and JEV serocomplex cross-
reactive mAbs. Thus, the JEV type-specific epitopes
probably do not overlap with flavivirus group cross-
reactive and JEV serocomplex cross-reactive epitopes. Our
previous report showed that using G106K/L107D double-
mutant JEV VLPs as ELISA antigens had no effect on assay
sensitivity, but dramatically increased the specificity in
distinguishing acute JEV infection from other flavivirus
infections in humans (Chiou et al., 2008). Studies
incorporating amino acid residue(s) of EDIII and W101G
of EDII into G106K/L107D double-mutant JEV VLPs may
greatly improve the specificity of antigens and vaccine
design.
METHODS
VLP expression plasmid. We used the recombinant expression
plasmid pVAX-JEi as the template DNA for both site-directed
mutagenesis and the transient expression of JEV WT recombinant
antigen (see below) (Chang et al., 2000, 2007; Hunt et al., 2001). The
pVAX-JEi includes the human cytomegalovirus (CMV) early gene
promoter, JEV signal sequence, JEV premembrane/membrane (prM/
M) and E gene region in its entirety, intron, bovine growth hormone
poly(A) signal and a kanamycin-resistance gene.
Site-directed mutagenesis. Site-specific mutations, as shown in
Table 1, were introduced into the JEV E gene of the pVAX-JEi
plasmid using a QuikChange Multi site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s recommended proto-
cols. Clones were sequenced across the entire prM–E region to
identify the correct mutant. Automated DNA sequencing was
performed with an ABI 3130xl genetic analysis system (Applied
Biosystems) and sequences were analysed with Lasergene software
(DNASTAR).
WT and mutant VLP expression. COS-1 cells (ATCC CRL 1650;
ATCC) were grown at 37 uC with 5 % CO2 in Dulbecco’s modified
Eagle’s minimal essential medium (Gibco) supplemented with 10 %
heat-inactivated FBS (HyClone Laboratories, Inc.). For transforma-
tion, 0.5 ml COS-1 cell suspension (1.56107 cells ml21) was
electroporated with 20 mg plasmid DNA in a 0.4 cm electrode gap
cuvette with a Bio-Rad Gene Pulser II set at 250 V and 975 mF. The
transformed COS-1 cells were seeded into individual 75 cm2 culture
flasks containing 50 ml growth medium and allowed to recover at
37 uC overnight, after which time they were continually maintained at
28 uC in serum-free medium (SFM4MegaVir; HyClone). Tissue-
culture medium was harvested every 3 days, clarified by centrifugation
at 10 000 r.p.m. for 30 min at 4 uC in a F-16/250 rotor (Beckman
Coulter) and stored at 4 uC for further analysis. The selected mutant
VLPs were concentrated by centrifugation at 19 000 r.p.m. for 16 h in a
type 19 rotor (Beckman Coulter), resuspended in 1 : 100 or original
volume, further purified by centrifugation at 39 000 r.p.m. for 4 h in a
SW41 rotor (Beckman Coulter) and resuspended in the same volume
of 16 TNE buffer (50 mM Tris, 140 mM NaCl, 5 mM EDTA). The E/
prM ratios for the selected WT and mutant VLPs were estimated by
Western blot with a 1 : 500 dilution of JEV-infected swine serum
obtained from our previous study. The estimated E/prM ratio was used
to determine the potential influence of mutations on prM processing
and maturation (Fig. S1).
In order to map the group and complex cross-reactive epitopes on the
JEV E glycoprotein, amino acid substitutions were introduced into a
WT JEV prM/E protein expression plasmid that directs the assembly
of VLPs when transfected into mammalian cell culture. Substitutions
at residues that were chosen based on previous reports or biological
function were introduced into each of the three domains of the JEV E
protein, and included I135 and E138 of EDI; W101, G104, G106 and
L107 of EDII; and T305, E306, K312, A315, S329, S331, G332 and
D389 of EDIII (Table S1). WT and mutant plasmids were
transformed into COS-1 cells for VLP expression and the cells were
incubated at 28 uC to increase VLP secretion into culture supernatant.
End points for tissue-culture fluid containing secreted JEV VLPs
ranged from 1 : 32 to 1 : 4096 when titrated in an Ag-ELISA. Secreted
antigen concentrations were standardized for mAb screening by
selecting the antigen concentration producing an A450 value of
approximately 1.0 with polyclonal anti-JEV MHIAF, which was
equivalent to 40 ng 20 % sucrose cushion-purified VLPs (data not
shown).
mAb panel. When selecting mAbs for use in antigen characterization,
we specifically chose a variety of group cross-reactive, JEV
serocomplex cross-reactive, and JEV type-specific mAbs that had
been raised against a diverse assortment of flaviviruses (Gentry et al.,
1982; Kimura-Kuroda & Yasui, 1983, 1986; Roehrig et al., 1983).
mAbs 4G2, 23-1, 23-2, 6B3B-3, 5-2 and 6B6C-1 are flavivirus group
cross-reactive (recognizing viruses from all major pathogenic
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serocomplexes of flaviviruses) and are non- to weakly NT. mAbs 16,
6B4A-10, 1B5D-1, 109, 203, 2B5B-3 and 7A6C-5 exhibit various levels
of cross-reactivity with viruses within the JEV serocomplex and are
non-NT as well. J3 14 H5-2, 112, 2F2, 2H4 and 503 are the JEV-
specific mAbs used in this study (Kimura-Kuroda & Yasui, 1986).
mAb reactivity with VLPs. The panel of mAbs was used to
determine end points of mAb reactivity with mutated and WT
antigens in Ag-ELISA as described previously (Crill & Chang, 2004).
Secreted antigen concentrations were standardized for mAb screening
by selecting the antigen concentration producing an A450 value of
approximately 1.0 with polyclonal anti-JEV MHIAF, which was
equivalent to 40 ng 20 % sucrose cushion-purified VLPs (data not
shown). Briefly, Immulon II HB flat-bottomed 96-well plates
(Dynatech Industries, Inc.) were coated with rabbit anti-JEV
hyperimmune serum using coating buffer (0.015 M sodium carbon-
ate, 0.035 M sodium bicarbonate, pH 9.6) and incubated overnight at
4 uC. Wells were blocked with 300 ml StartingBlock (PBS) blocking
buffer (Pierce). WT and mutant antigens were captured during a 1 h
incubation at 37 uC. Plates were subsequently washed three times.
mAbs were diluted serially in 5 % milk, and 50 ml was added to the
wells before incubation at 37 uC for 1 h. Plates were washed three
times, and then mAbs were detected with HRP-conjugated goat anti-
MHIAF at a 1 : 5000 dilution in PBS containing 5 % milk. Bound
conjugate was detected by adding 75 ml 3,39,5,59-tetramethylbenzidine
(TMB; Neogen Corp.) substrate and incubating at room temperature
for 10 min. The substrate reaction was stopped with 50 ml 1 M
H2SO4, and A450 was measured with an EL 312e Bio-Kinetics
microplate reader (Bio-Tek Instruments, Inc.). The end-point titre of
mAb reactivity was confirmed by repeat titration.
JEV cross-reactive epitopes. A homology model for the JEV E
protein was produced using the published atomic coordinates for
DENV-2 and TBEV and the SWISS-MODEL workspace (http://
swissmodel.expasy.org/workspace/). Preferred potential epitopes were
identified by Ag-ELISA using mutant JEV VLPs mapped onto an E
dimer.
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